Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OptimizeRx Corporation - Common Stock (NQ: OPRX )

8.380 -0.470 (-5.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 247,235
Open 8.840
Bid (Size) 7.250 (8)
Ask (Size) 12.50 (1)
Prev. Close 8.850
Today's Range 7.920 - 9.270
52wk Range 6.920 - 16.64
Shares Outstanding 17,618,607
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OPRX Stock Earnings: OptimizeRx Beats EPS, Misses Revenue for Q2 2024
OPRX stock results show that OptimizeRx beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
OptimizeRx Reports Second Quarter 2024 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire

Performance

YTD
-40.31%
-40.31%
1 Month
-17.76%
-17.76%
3 Month
-20.49%
-20.49%
6 Month
-46.07%
-46.07%
1 Year
-33.33%
-33.33%

More News

Read More
OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach Patients
From OptimizeRx Corporation
Via GlobeNewswire
Critical Insights From OptimizeRx Analyst Ratings: What You Need To Know
Via Benzinga
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
From OptimizeRx Corporation
Via GlobeNewswire
Expert Ratings For OptimizeRx
Via Benzinga
Where OptimizeRx Stands With Analysts
Via Benzinga
OPRX Stock Earnings: OptimizeRx Beats Revenue for Q4 2023
Via InvestorPlace
OptimizeRx Earnings Preview
Via Benzinga
Gold Rises Over 1%; Arcos Dorados Shares Fall After Q1 Results
Via Benzinga
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Surges 150 Points; Retail Sales Flat For April
Via Benzinga
OPRX Stock Earnings: OptimizeRx Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
OptimizeRx Reports First Quarter 2024 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx to Participate in Upcoming Investor Conferences
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row
From OptimizeRx Corporation
Via GlobeNewswire
7 Top Undervalued Stocks Primed for a Multibagger Recovery
Via InvestorPlace
Earnings Scheduled For March 28, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.